Association Between LDL-to-HDL Cholesterol Ratio and Albuminuria in Patients With Type 2 Diabetes Mellitus: A Cross- Sectional Study
DOI:
https://doi.org/10.19166/med.v15i3.11493Keywords:
Type 2 Diabetes Mellitus, albuminuria, diabetic kidney disease, LDL/HDL ratioAbstract
Background:
Dyslipidemia plays a role in the pathogenesis of diabetic kidney disease, yet the clinical utility of the LDL/HDL ratio for detecting early renal involvement remains uncertain. This study evaluated the association between LDL/HDL ratio and albuminuria in type 2 diabetes mellitus (T2DM) patients.
Methods:
A cross-sectional study was conducted using medical records of adults with T2DM at Siloam Hospital Lippo Village, Indonesia. Patients with complete lipid profiles and urine albumin–creatinine ratio (ACR) data were included. The LDL/HDL ratio was analyzed in relation to albuminuria. Receiver operating characteristic (ROC) analysis determined the optimal cutoff. The ratio was dichotomized using this cutoff, and associations with albuminuria were evaluated using chi-square tests and Poisson regression with robust variance to estimate adjusted prevalence ratios (aPRs).
Result:
A total of 95 patients were analyzed, of whom 46.3% had albuminuria. The LDL/HDL ratio correlated with ACR (ρ=0.528, p<0.001). ROC analysis showed good discrimination for albuminuria (AUC 0.796; 95%CI 0.704–0.888), with a bootstrap 95%CI 0.700–0.881. The optimal cutoff was 2.435, yielding 77.3% sensitivity and 74.5% specificity. Albuminuria was more frequent in patients with LDL/HDL ≥2.435 than in those below the cutoff (72.3% vs. 20.8%; p<0.001). LDL/HDL ≥2.435 was independently associated with albuminuria (aPR 3.03; 95%CI 1.82–5.26; p<0.001). Hypertension, older age, and higher HbA1c were also significant predictors.
Conclusion:
The LDL/HDL ratio showed acceptable discriminatory performance and was independently associated with albuminuria in patients with T2DM. This simple index may serve as an adjunctive marker for renal risk stratification, pending external validation in larger prospective studies.
References
1. Ong KL, Stafford LK, McLaughlin SA, et al. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. The Lancet 2023; 402: 203–234.
2. World Health Organization. Global report on diabetes. Geneva: World Health Organization, https://iris.who.int/handle/10665/204871 (2016, accessed 3 August 2025).
3. Pinchevsky Y, Butkow N, Raal FJ, et al. Demographic and Clinical Factors Associated with Development of Type 2 Diabetes: A Review of the Literature. Int J Gen Med 2020; 13: 121–129.
4. Tuttle KR, Bakris GL, Bilous RW, et al. Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care 2014; 37: 2864–2883.
5. Chatterjee A, Tumarin J, Prabhakar S. Role of inflammation in the progression of diabetic kidney disease. vp 2024; 8: N/A-N/A.
6. Sun K, Lin D, Li F, et al. Discordant associations of lipid parameters with albuminuria and chronic kidney disease: a population-based study. Lipids Health Dis 2015; 14: 152.
7. Russo GT, De Cosmo S, Viazzi F, et al. Plasma Triglycerides and HDL-C Levels Predict the Development of Diabetic Kidney Disease in Subjects With Type 2 Diabetes: The AMD Annals Initiative. Diabetes Care 2016; 39: 2278–2287.
8. Hirano T, Satoh N, Kodera R, et al. Dyslipidemia in diabetic kidney disease classified by proteinuria and renal dysfunction: A cross‐sectional study from a regional diabetes cohort. J Diabetes Investig 2022; 13: 657–667.
9. Hirano T. Pathophysiology of Diabetic Dyslipidemia. J Atheroscler Thromb 2018; 25: 771–782.
10. Nugnes M, Baldassarre M, Ribichini D, et al. Association between Albumin Alterations and Renal Function in Patients with Type 2 Diabetes Mellitus. Int J Mol Sci 2024; 25: 3168.
11. Khadka S, Yadav GK, Subedi P, et al. Association of urinary albumin-to-creatinine ratio with lipid abnormalities and glycemic control in patients with type 2 diabetes mellitus. Ann Med Surg (Lond) 2023; 85: 4329–4333.
12. He L, Yi B, Zhang D, et al. Achieved low-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio predicts the pathophysiological evolution of lipid-rich plaques in acute coronary syndromes: an optical coherence tomography study. Front Cardiovasc Med 2023; 10: 1181074.
13. Li M, Wang Y, Yao Q, et al. Association between Lipoprotein(a) and diabetic nephropathy in patients with type 2 diabetes. Front Endocrinol (Lausanne) 2023; 14: 1337469.
14. Oliveira HCF, Raposo HF. Cholesteryl Ester Transfer Protein and Lipid Metabolism and Cardiovascular Diseases. Adv Exp Med Biol 2020; 1276: 15–25.
15. Opazo-Ríos L, Mas S, Marín-Royo G, et al. Lipotoxicity and Diabetic Nephropathy: Novel Mechanistic Insights and Therapeutic Opportunities. Int J Mol Sci 2020; 21: 2632.
16. Wang C, Wang L, Liang K, et al. Poor Control of Plasma Triglycerides Is Associated with Early Decline of Estimated Glomerular Filtration Rates in New-Onset Type 2 Diabetes in China: Results from a 3-Year Follow-Up Study. J Diabetes Res 2020; 2020: 3613041.
17. Jang H-S, Noh MR, Kim J, et al. Defective Mitochondrial Fatty Acid Oxidation and Lipotoxicity in Kidney Diseases. Front Med (Lausanne) 2020; 7: 65.
18. Russo G, Piscitelli P, Giandalia A, et al. Atherogenic dyslipidemia and diabetic nephropathy. J Nephrol 2020; 33: 1001–1008.
19. Roumeliotis S, Roumeliotis A, Georgianos PI, et al. Oxidized LDL Is Associated with eGFR Decline in Proteinuric Diabetic Kidney Disease: A Cohort Study. Oxid Med Cell Longev 2021; 2021: 2968869.
20. Hwang SW, Lee T, Uh Y, et al. Urinary albumin creatinine ratio is associated with lipid profile. Sci Rep 2024; 14: 14870.
21. Thamrin H, Sutjahjo A, Pranoto A, et al. Association of Metabolic Syndrome with Albuminuria in Diabetes Mellitus Type 2. Biomolecular and Health Science Journal 2019; 2: 82–88.
22. Abdelwahid HA, Dahlan HM, Mojemamy GM, et al. Predictors of microalbuminuria and its relationship with glycemic control among Type 2 diabetic patients of Jazan Armed Forces Hospital, southwestern Saudi Arabia. BMC Endocr Disord 2022; 22: 307.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Jeremia Siregar, Michelle Audrey Widuri Hutapea, Angeline Tancherla, Andree Kurniawan, Stephanie Marisca
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC-BY-SA 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website). The final published PDF should be used and bibliographic details that credit the publication in this journal should be included.
